Cargando…

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study

AIMS: To investigate cardiovascular (CV) safety and event rates for dapagliflozin versus other glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the main inclusion criteria and outcomes from the DECLARE‐TIMI 58 study. METHODS: Patients with new initiation of dap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Norhammar, Anna, Bodegård, Johan, Nyström, Thomas, Thuresson, Marcus, Nathanson, David, Eriksson, Jan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593417/ https://www.ncbi.nlm.nih.gov/pubmed/30609272 http://dx.doi.org/10.1111/dom.13627

Ejemplares similares

Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
por: Nyström, Thomas, et al.
Publicado: (2017)

Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
por: Kristófi, Robin, et al.
Publicado: (2021)

Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data
por: Kristófi, Robin, et al.
Publicado: (2022)

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2017)

Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study
por: Escobar, Carlos, et al.
Publicado: (2022)

History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case–control study
por: Ritsinger, Viveca, et al.
Publicado: (2023)

IDF2022-0622 Mortality and cardiorenal disease in type 1 and type 2 diabetes after COVID-19 and influenza hospitalization in Sweden
por: Kristófl, R., et al.
Publicado: (2023)

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
por: Mosenzon, Ofri, et al.
Publicado: (2022)

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
por: Nathanson, David, et al.
Publicado: (2017)

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
por: McEwan, Phil, et al.
Publicado: (2021)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2018)

Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study
por: Jernberg, Tomas, et al.
Publicado: (2019)

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
por: Birkeland, Kåre I., et al.
Publicado: (2019)

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
por: Norhammar, Anna, et al.
Publicado: (2022)

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
por: Hasvold, Pål, et al.
Publicado: (2015)

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
por: Kosiborod, Mikhail, et al.
Publicado: (2017)

Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
por: Norhammar, Anna, et al.
Publicado: (2023)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality
por: Iyer, Nandhini, et al.
Publicado: (2023)

The TIMI Study Group’s Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-
por: Toda Kato, Eri, et al.
Publicado: (2021)

Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
por: Kohsaka, Shun, et al.
Publicado: (2020)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

TIMI perfusion grade compared to TIMI flow in prediction of infarct size and microvascular obstruction measured by contrast-enhanced MRI
por: Fuernau, Georg FK, et al.
Publicado: (2009)

Phonological similarity between words is represented in declarative memory as spatial distance
por: Tuena, Cosimo, et al.
Publicado: (2023)

Importance of the TIMI frame count: implications for future trials
por: Appleby, Mark A, et al.
Publicado: (2000)

Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial
por: Furtado, Remo H. M., et al.
Publicado: (2020)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Validity of TIMI Score for Predicting 14-Day Mortality of Non-ST Elevation Myocardial Infarction Patients
por: Kumar, Dileep, et al.
Publicado: (2021)

GRACE Score among Six Risk Scoring Systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) Demonstrated the Best Predictive Value for Prediction of Long-Term Mortality in Patients with ST-Elevation Myocardial Infarction
por: Littnerova, Simona, et al.
Publicado: (2015)

Gramado Declaration: The Impact of 20 Years of Cardiovascular Prevention
por: Achutti, Aloyzio, et al.
Publicado: (2017)

Declarations
Publicado: (2015)

Far Beyond Declarative and Non-Declarative Memories
por: Dere, Ekrem, et al.
Publicado: (2014)

Implications of the PEGASUS-TIMI 54 trial for US clinical practice
por: Bradley, Steven M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8nt1vti6jueb3pih1haft3vqmn